The Hello Bar is a simple web toolbar that engages users and communicates a call to action.
You are here: Home / Archives for Novartis

Novartis drug Afinitor® extends progression-free survival in patients with advanced pancreatic NET

February 9, 2011 By Leave a Comment

Basel, February 9, 2011 – The New England Journal of Medicine (NEJM) published a study today that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET)[1]. Data from the study, RADIANT-3 (RAD001 [...]

Filed Under: Pharmacy Tagged With: , , , ,

Novartis receives approval in the European Union for Menveo®, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease

March 18, 2010 By Leave a Comment

Basel, March 18, 2010 – Novartis announced today that the European Commission (EC) granted a Marketing Authorization for Menveo® (Meningococcal Group A, C, W135 and Y conjugate vaccine) in all 27 European member states. Menveo is indicated for the active immunization of adolescents (from 11 years of age) and adults at risk of exposure to [...]

Filed Under: Uncategorized Tagged With: , ,

Exploratory trial shows no incremental benefit of aliskiren add-on therapy in improving changes to cardiac shape in heart attack patients

March 16, 2010 By Leave a Comment

Basel, March 16, 2010 – The addition of the cardiovascular medicine aliskiren to standard therapy for patients recovering from a heart attack showed some positive effects in helping limit changes in the heart’s shape and function, but did not demonstrate a statistically significant benefit, according to new clinical trial results[1]. Data from the ASPIRE study [...]

Filed Under: Pharmacy Tagged With: , ,

NAVIGATOR shows valsartan delayed progression to type 2 diabetes in at-risk cardiovascular patients with impaired glucose tolerance

March 14, 2010 By Leave a Comment

Basel, March 14, 2010 – Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a common pre-diabetic condition. Primary data from the NAVIGATOR (Nateglinide And Valsartan in [...]

Filed Under: Pharmacy Tagged With: , , ,

Alabama Supreme Court Overturns Verdict Against Novartis

October 16, 2009 By Leave a Comment

EAST HANOVER, N.J., – The Alabama Supreme Court today overturned a jury verdict against Novartis Pharmaceuticals Corporation (NPC), and directed entry of judgment in favor of NPC. The State of Alabama had claimed prices provided by NPC to reporting services resulted in overpayment to pharmacists and doctors in the Alabama State Medicaid system, and a [...]

Filed Under: Pharmacy Tagged With:
Newer Posts »
HTML Codes

© Rx Times 2006 - 2012. All rights reserved. All products denoted with ™ and ® are trademarks or registered trademarks of Rx Times, LLC and/or its affiliates.